Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells-Reference-Cited by-同舟云学术

Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells

Published:2019-07-19 Issue:8 Volume:68 Page:1341-1350
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Urakawa Shinya,Yamasaki Makoto,Goto Kumiko,Haruna Miya,Hirata Michinari,Morimoto-Okazawa Akiko,Kawashima Atsunari,Iwahori Kota,Makino Tomoki,Kurokawa Yukinori,Yamada Tomomi,Mori Masaki,Doki Yuichiro,Wada Hisashi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-019-02366-0.pdf

Reference42 articles.

1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388(10060):2654–2664. https://doi.org/10.1016/S0140-6736(16)30354-3

2. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, Ono H, Tanabe S, Kaminishi M (2013) Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16(1):1–27. https://doi.org/10.1007/s10120-012-0163-4

3. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471. https://doi.org/10.1016/S0140-6736(17)31827-5

4. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y (2017) Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 18:631–639. https://doi.org/10.1016/S1470-2045(17)30181-X

5. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S (2016) Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22(6):679–684. https://doi.org/10.1038/nm.4086

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. Construction of the prediction model for multiple myeloma based on machine learning;International Journal of Laboratory Hematology;2024-05-31

3. Development and validation of a novel prognostic lncRNA signature based on the APOBEC3 family genes in gastric cancer;Heliyon;2024-03

4. N⁶-methylation in the development, diagnosis, and treatment of gastric cancer;Journal of Translational Internal Medicine;2024-02-01

5. Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Immunology;2023-11-27